ZBTB16
ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.
Overview
Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.98, genetic association 0.43, somatic mutation 0.84, animal model 0.64). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Oesophageal Squamous Cell Carcinoma, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.
- 1 · What it is
ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.
- 2 · What goes wrong in cancer
Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters.
- 3 · How drugs use it
No product in this corpus aims at ZBTB16 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:12930 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q05516 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000109906 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: prostate cancer 0.51, melanoma 0.52, skin cancer 0.55, breast cancer 0.53, lung cancer 0.52 (GraphQL API, CC0)); IntOGen ZBTB16 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Nucleus, nuclear body (UniProt). Locus 11q23.2 (HGNC).
- Prostate cancer: Open Targets association 0.51 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCC)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)
- Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)
- Oesophageal squamous cell carcinoma: IntOGen driver in 1 cohort (ESCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZBTB16" OR ABSTRACT:"ZBTB16" OR TITLE:"zinc finger and BTB domain containing 16" OR ABSTRACT:"zinc finger and BTB domain containing 16" OR TITLE:"Zinc finger and BTB domain-containing protein 16" OR ABSTRACT:"Zinc finger and BTB domain-containing protein 16" OR TITLE:"ZNF145" OR ABSTRACT:"ZNF145") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZBTB16, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetFCRL4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetIKBKB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetKAT6A
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, Breast cancer (all types).
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, Breast cancer (all types).